Haisike announced that its subsidiary Shanghai Haishengnuo Pharmaceutical Technology Co., Ltd. recently received the "Acceptance Notice" issued by the National Medical Products Administration. The name of the drug is HSK 42,000 tablets, the dosage form is tablets, and the indication is intended to be used for the treatment of advanced solid tumors. HSK42000 is an oral, potent and highly selective small molecule inhibitor independently developed by the company. According to the chemical drug registration classification issued by the State Food and Drug Administration, this product belongs to Class 1 chemical drugs. Preclinical research results show that HSK42000 significantly inhibits tumor cell proliferation activity, exhibits excellent anti-tumor efficacy, and also shows good tolerance and a large safety window. It is a very The development of potential small molecule anti-tumor drugs is expected to provide a new treatment option for patients with advanced solid tumors.